Thiamine-boosting therapy for Alzheimer’s: understanding how benfotiamine may reduce harmful AGE in DP patients
Official title: Mechanistic links between the benefits of pharmacologically high thiamine (vitamin B1) in Alzheimer's disease to Advanced Glycation Endproducts (AGE)
Funded at Weill Medical Coll of Cornell Univ · NIH-11627145 · Data updated 2026-11-12
A medication-based approach using high-dose vitamin B1 (benfotiamine) is studied to help people with Alzheimer's by reducing harmful sugar-related molecules.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Weill Medical Coll of Cornell Univ NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | February 1, 2024 |
| Project end | January 31, 2029 |
| Funding year | 2026 |
| Award (this year) | $1,386,528 |
| NIH project number | 7R01AG082228-04 |
| Project ID | NIH-11627145 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults diagnosed with Alzheimer’s disease or AD-like pathology, including APOE4 carriers who may respond differently to high-thiamine therapy.
✕Less likely to help
Patients without Alzheimer’s disease pathology or those unlikely to respond due to genotype or disease stage may see limited benefit.
What this research studies
This project explores how pharmacological thiamine could help people with Alzheimer’s disease by lowering advanced glycation endproducts (AGE) that damage brain cells. Building on prior clues from animal models and a small clinical trial, the study aims to uncover the mechanisms by which benfotiamine may reduce AGE formation and related pathology, and how APOE genotype might influence response. Researchers will examine protein- and lipid-bound AGE changes, their sites of modification, and how these relate to cognitive symptoms and disease progression. The work includes translational experiments in human samples and disease-relevant models to map how thiamine interacts with AD features at the molecular level. Outcomes could sharpen strategies for using thiamine-based therapies in AD, potentially guiding personalized approaches for APOE4 carriers.
Why it matters
Potential benefit: If successful, the findings could clarify who might benefit most from benfotiamine therapy and how to optimize its use to slow or alter Alzheimer’s disease progression.
How similar studies have gone: Previous studies hint that high-thiamine can lower AGE and improve symptoms, but detailed mechanisms and genotype effects remain to be clarified.
Where this research is happening
-
Weill Medical Coll of Cornell Univ
New York, United States Active
Researchers
- Principal investigator: Gibson, Gary E — Weill Medical Coll of Cornell Univ
- Study coordinator: Gibson, Gary E
Related research
Other NIH-funded projects on the same topics.
-
Understanding how brain activity changes may drive Alzheimer’s disease progression in a mouse model
Researchers are testing how changes in brain signals and protein cleanup processes affect the development of Alzheimer’s disease in mice.
-
Non-invasive tears biomarker for early Alzheimer's in LMICs
A low-cost, tear-based biomarker approach aims to detect early Alzheimer’s disease in older adults in Peru and similar settings.
-
Turning APOE4 into protective APOE2 or APOE3Christchurch to help with Alzheimer’s
A patient-facing explanation of a treatment idea that aims to change a genetic risk factor for Alzheimer's disease in the brain.
-
Telomerase in Alzheimer’s Disease: how aging biology could influence memory and brain health
Researchers are exploring a new brain-aging mechanism linked to telomerase, with potential to slow or modify Alzheimer’s disease in people and improve cognitive function.
-
Biomarkers of Alzheimer’s Disease: Sensory, Motor, and Cognitive Clues
Researchers are testing simple sensory and movement tasks to find early signs of Alzheimer’s disease so they can diagnose and treat people sooner.
-
Selective Targeting of Nurr1 for Alzheimer’s Disease
A small study tests new brain-targeted compounds to help people with Alzheimer’s by reducing inflammation and protecting brain cells.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.